Table 4 Eradication rate in susceptible and resistant strainsa[8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30, 33,34,35,36,37,38]
From: Toward population specific and personalized treatment of Helicobacter pylori infection
Clarithromycin susceptible | Clarithromycin resistant | |
|---|---|---|
Triple therapy: PPI-amoxicillin-clarithromycin | ||
7 days | 88.5% (2428/2744) | 25.8% (121/469) |
10 days | 90.8% (267/294) | 44% (37/84) |
14 days | 89.6% (841/939) | 43.3% (55/127) |
Sequential therapy | ||
10 days | 91% (1470/1616) | 65% (225/346) |
14 days | 98.1% (304/310) | 72.2% (26/36) |
Concomitant therapy | ||
5 days | 84.4% (76/90) | 50% (2/4) |
7 days | 96.3% (181/188) | 83.3% (20/24) |
10 days | 94.5% (598/633) | 80.5% (120/149) |
Hybrid therapy | ||
10–14 days | 96.8% (418/432) | 81.8% (117/143) |
Bismuth quadruple therapy | ||
7 days | 87.2% (321/368) | 87.2% (321/368) |
10 days | 93.9% (512/545) | 91.4% (139/152) |
14 days | 96.9% (94/97) | 92.3% (12/13) |
Bismuth quadruple therapy | Metronidazole susceptible | Metronidazole resistant |
7 days | 92% (252/274) | 73.4% (69/94) |
10 days | 94.3% (764/810) | 89.8% (397/442) |
14 days | 96.1% (99/103) | 93.2% (41/44) |
Levofloxacin susceptible | Levofloxacin resistant | |
Triple therapy: PPI-amoxicillin-levofloxacin | 81.8% (189/231) | 33.3% (10/30) |